According to Missling all patients in all trials will have full exome sequencing.
So far no trials have used data from this genetic screening to select patients for inclusion criteria and enrollment in trials.
Anavex have clearly learned a lot from the genetic screening and other biomarkers to characterise both patients and the pathologies/genetic pathways and how they change in course of the PD/PDD, AD and Rett trials.
With the readouts of the P2b/3 AD, the PD/PDD OLE and Rett Excellence trials, more will be learned and assessed before applying Precision Medicine selection criteria to planned and yet to be planned trials e.g. in AD with A2-73/3-71.
Pretty sure collecting, analysing and understanding this data, including awaiting the above trial data, is behind the extended time taken to initiate new trials.
Of course we are all routing for approval from the upcoming P2b/3 readout and will know the Top-Line Data in less than 2 weeks.
Regardless, I find the thorough work Anavex is doing to uncover upstream biological mechanisms behind CNS indication pathologies exciting and admirable. I have little doubt that work will pay bonus from future Precision Medicine trials selecting the right patients, for the right drug at the right time.
News 
Market Data 
Discover 
AI
